Agilent Technologies acquires Resolution Bioscience

Agilent Technologies acquired Resolution Bioscience for $550 million cash plus up to $145 million milestones, a transaction completed in April 2021, structured as cash plus contingent consideration.

Resolution Bioscience operates in Diagnostics and Genomics, is based in Kirkland, Washington, USA. Resolution Bioscience develops next-generation-sequencing precision-oncology solutions, including a noninvasive, CLIA-certified liquid-biopsy platform that detects actionable cancer mutations from a standard blood sample.

Pairing Resolution's liquid biopsy with Agilent's tissue-based companion diagnostics and global commercial and regulatory scale deepened Agilent's role in the fast-growing NGS precision-oncology market. (Agilent later wound down the Resolution NGS operations and recorded a related impairment.)

By adding Resolution Bioscience's liquid biopsy-based diagnostic technologies to our portfolio, we are strengthening Agilent's offering to our biopharma customers and boosting the growth of our diagnostics and genomics business.Mike McMullen, President and CEO, Agilent

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.